MAC Lung Disease – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

MAC Lung Disease Emerging Therapy and TPP Insights

Thelansis’s “MAC Lung Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

MAC Lung Disease Overview

MAC Lung Disease is a chronic nontuberculous mycobacterial infection with heterogeneous clinical progression, frequently occurring in patients with underlying structural lung abnormalities such as bronchiectasis or cavitary disease. Prolonged multidrug antimycobacterial therapy remains the foundation of treatment, typically incorporating a macrolide and ethambutol, with therapy generally continuing for at least 12 months after sputum culture conversion. However, treatment is associated with substantial pill burden, adverse effects, drug interactions, antimicrobial resistance, and microbiological relapse or treatment failure. For patients with refractory MAC Lung Disease who remain culture-positive after at least six months of guideline-based therapy, inhaled liposomal amikacin (ALIS) provides a targeted pulmonary-delivery option and is FDA-approved as part of combination therapy. The development landscape is now expanding beyond ALIS toward additional inhaled formulations, including Phase 3 inhaled clofazimine, as well as novel and repurposed antimycobacterial agents for refractory or drug-resistant disease. Key opportunities remain in improving localized drug exposure, shortening treatment duration, reducing toxicity, limiting resistance, and achieving more durable microbiological control.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)